Study finds GP breast cancer guidelines miss 95% of at-risk young women

A woman under 50 walks into her GP's surgery with concerns about breast cancer risk. The doctor checks the guidelines—the ones issued by the National Institute for Health and Care Excellence, the body that sets clinical standards across the NHS. The guidelines ask a straightforward question: Is there a strong family history of the disease? If the answer is no, the woman is sent home without referral for specialist assessment or early screening. She is, by the system's logic, not at risk. She is, statistically, wrong.

Research published in the British Journal of Cancer reveals that the current Nice criteria for identifying women at elevated breast cancer risk are missing roughly 95% of women under 50 who will develop the disease within the next decade. The study, conducted by researchers at the University of Cambridge and the Institute of Cancer Research in London, compared existing guidelines against a more comprehensive risk assessment model called Boadicea, funded by Cancer Research UK. When the two approaches were applied to the same population, Boadicea identified eight times as many at-risk women as the Nice criteria did.

The gap exists because of a single, critical assumption embedded in current practice. The Nice guidelines hinge almost entirely on family history—the presence of breast cancer in close relatives. But the research found that 73% of women under 50 who go on to develop breast cancer within a decade have no family history at all. They are, by definition, invisible to the system designed to catch them. These women miss the chance for early specialist assessment, additional screening, or preventive treatments that might alter the course of their disease. Breast cancer remains the most common cancer worldwide and a leading cause of death in women under 50. Early identification of risk can mean the difference between catching the disease at a treatable stage and discovering it later, when options narrow.

Boadicea takes a wider lens. Beyond family history, it examines reproductive patterns, lifestyle factors, and genetic markers. This more granular approach identifies women whose risk is elevated not because of what runs in their family, but because of the particular constellation of their own biology and circumstances. The trade-off is obvious: the Nice criteria are simple to apply in a busy GP practice. A doctor can ask three questions and move on. Boadicea requires more data, more time, potentially genetic testing, and specialist input. It demands resources that the NHS, already stretched, would need to find.

Dr. Juliet Usher-Smith of Cambridge framed the stakes plainly: the current guidelines are missing the majority of women who need early intervention. "It's time to look again at these criteria," she said. Prof. Montserrat García-Closas of the Institute of Cancer Research acknowledged the bind. A full risk assessment would catch far more women, but it would place a heavy burden on NHS resources. The choice, she suggested, is not between perfect and imperfect—it is between simple-and-incomplete and comprehensive-and-costly.

Breast Cancer Now, which supported the study, called for the findings to be considered as part of Nice's current review of family history guidelines. The charity emphasized that any changes must come with adequate funding to implement them fairly across the NHS. A Nice spokesperson responded cautiously, welcoming the study's potential while stopping short of immediate action. The current evidence, they said, does not yet warrant changing existing guidelines. Nice remains open to reviewing new data as information on feasibility and clinical outcomes emerges.

What this means for the woman in the GP's surgery is still uncertain. She may continue to be sent home without referral, her risk unassessed, her options unexplored. The research has named the problem with precision. Whether the system will move to solve it remains an open question.